's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

»'s Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » New - Pacific Therapeuitics » Post A Reply

Post A Reply
Login Name:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    

HTML is not enabled.
UBB Code™ is enabled.


Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?

Disable Graemlins in this post.


T O P I C     R E V I E W
djk  - posted
"The once a day tablet of PTL-202 uses the multi-layer technology developed by IntelGenx Corp. of Montreal."

Pacific Therapeutics Ltd. (PT: CNSX)

Pacific Therapeutics is a Specialty Pharmaceutical Company focused on the identification, development and sales of drug candidates to treat diseases of the liver and lungs caused by excessive and progressive tissue scarring, called fibrosis.

Pacific Therapeutics’ business and drug development strategy reduces risk, time and the capital costs of developing new drug therapies for liver and lung diseases caused by fibrosis. By combining existing approved drugs that have already known safety and toxicity profiles, the company eliminates the inherent risks involved with basic pre clinical research and animal testing.

Pacific Therapeutics’ lead drug candidate; PTL-202 is set for Phase 1 clinical trials in 2012. PTL-202 is a combination of drugs that have been approved by the FDA to treat diseases other than fibrosis. PTL-202 is being developed by Pacific Therapeutics to treat a progressive lung scarring disease, named Idiopathic Pulmonary Fibrosis (IPF). More people die of annually IPF than either prostate or breast cancer. IPF is estimated to be a $2 billion market opportunity.

On July 12, 2011 Pacific Therapeutics engaged CRBIO (Clinical Research and Biosciences of Hyderabad, India to conduct a clinical trial with PTL-202 in a drug to drug interaction study in humans. CRBIO is the clinical trials a division of RA Chem Pharma Limited., India.

The once a day tablet of PTL-202 uses the multi-layer technology developed by IntelGenx Corp. of Montreal.

Pacific Therapeutics’ second drug candidate, PTL-303, is also a combination of drugs, one of which has been approved for human use in Japan. PTL-303 has been shown to be effective in the reduction of molecules that contribute to the development of diseases including, liver cirrhosis in humans. PTL-303 may be developed as a treatment to reduce the severity of progressive diseases like chronic liver disease.

Chronic liver disease which may lead to cirrhosis of the liver is responsible for over 1.4m deaths annually (WHO, World Health Report 2004) In the US chronic liver disease is among the top ten disease related causes of death (CDC, National Center for Health Statistics, 2004). This market is estimated to be $3.0 billion.

Share Capital - March 2012

Shares issued: 20,787,950
Escrowed shares: 10,031,001
Warrants & Options: 4,653,000
Fully Diluted: 25,440,950

52 wk hi-lo: 0.25-0.10


Contact Us | Message Board Home

© 1997 - 2021 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2